Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.
You may also be interested in...
Emerging Markets Earnings Roundup: Novartis, Eli Lilly (Part 4)
Novartis posted solid growth of 9% in Q1 in emerging markets, with China sales up 21%; Lilly reports strong sales in China lifted revenues by 11%.
Bayer’s Eylea Sees Good Start In Japan Thanks To Partnering
Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.